Eli Lilly stops disclosing early-stage pipeline, sparking debate
Eli Lilly has decided to no longer publicly disclose its Phase 1 pipeline, a shift from its previous transparency. The move comes as the company's GLP-1 drug leads global sales and its market valuation tops all other healthcare firms. Industry observers have responded with mixed opinions about the strategic change.
Related stories
Eli Lilly Cracks Down on Illicit Retatrutide Sales · Drug development
BioMarin acquires early-stage bone disease candidate in modest deal · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Lilly's move to hide Phase 1 pipeline draws mixed reviews.” Browse more stories.